US · RYTM
Rhythm Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boston, MA 02116
- Website
- rhythmtx.com
Price · as of 2025-12-31
$81.81
Market cap 6.19B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $58.74 | -28.2% |
| Intrinsic Value(DCF) | $292.32 | +257.32% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $27.28 | ||||
| 2018 | $27.92 | ||||
| 2019 | $18.05 | ||||
| 2020 | $26.09 | ||||
| 2021 | $9.73 | ||||
| 2022 | $19.60 | $77.78 | $1.19 | $0.00 | $0.00 |
| 2023 | $41.94 | $54.91 | $0.00 | $0.00 | $0.00 |
| 2024 | $50.79 | $42.00 | $12,204.66 | $0.00 | $0.00 |
| 2025 | $94.94 | $58.74 | $3,047.49 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Rhythm Pharmaceuticals, Inc.'s (RYTM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $58.74
- Current price
- $81.81
- AI upside
- -28.2%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$292.32
+257.32% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RYTM | Rhythm Pharmaceuticals, I… | $81.81 | 6.19B | -28% | +257% | — | — | -31.39 | 44.36 | 32.51 | -33.22 | — | 46.13 | 89.73% | -101.19% | -106.41% | -129.46% | 96.50% | -45.05% | 0.03 | -9.33 | 4.41 | 3.92 | 0.29 | -2834.00% | 4583.00% | 241.00% | -1.89% | -1.09 | 58.61% | 0.09% | -2.70% | 0.09% | -30.13 | -49.60 | 30.48 | 13.65 |
| ACLX | Arcellx, Inc. | $113.79 | 6.58B | -42% | — | — | — | -28.05 | — | — | -31.38 | -27.10 | — | 0.00% | — | — | -100.68% | 644.58% | -39.69% | — | -10.45 | — | — | 0.00 | 10350.00% | -10000.00% | 11938.00% | -3.31% | — | 541.60% | 0.00% | 0.00% | 0.02% | -25.37 | -30.21 | — | — |
| AKRO | Akero Therapeutics, Inc. | $54.65 | 4.5B | — | — | — | — | -11.22 | 3.77 | — | -7.43 | -37.70 | 3.77 | 0.00% | — | — | -39.22% | -1042.60% | -35.85% | 0.05 | -61.14 | 19.38 | 18.69 | 1.06 | 2976.00% | — | 5898.00% | -8.17% | -5.79 | -844.19% | 0.00% | 0.00% | 3.41% | -7.43 | -9.18 | — | 20.91 |
| ARVN | Arvinas, Inc. | $13.27 | 974.25M | +82% | -40% | -97% | — | -10.76 | 2.00 | 3.31 | -2.55 | — | 2.00 | 98.02% | -43.75% | -30.77% | -16.23% | 32.32% | -8.93% | 0.02 | — | 4.92 | 4.88 | 1.78 | -5379.00% | -30.00% | 559.00% | -31.73% | -1.92 | 77.55% | 0.00% | 0.00% | 15.59% | -1.67 | -0.70 | 0.73 | -0.54 |
| BDTX | Black Diamond Therapeutic… | $2.47 | 140.73M | — | — | — | — | -1.48 | 1.24 | — | -0.35 | — | 1.24 | 0.00% | — | — | -69.67% | -898.81% | -49.55% | 0.27 | — | 4.92 | 4.79 | 0.18 | -3245.00% | — | -666.00% | -60.22% | -3.03 | -710.82% | 0.00% | 0.00% | 0.00% | -0.34 | -0.43 | — | -5.31 |
| CGEM | Cullinan Therapeutics, In… | $15.50 | 915.68M | — | — | — | — | -2.79 | 0.79 | — | -0.43 | — | 0.79 | 0.00% | — | — | -32.10% | -214.36% | -30.30% | 0.00 | — | 13.53 | 13.12 | 0.48 | -1572.00% | — | 805.00% | -31.02% | -4.74 | -158.17% | 0.00% | 0.00% | 0.00% | -0.36 | -0.49 | — | 7.79 |
| KNSA | Kiniksa Pharmaceuticals, … | $44.49 | 3.3B | +56% | +8,673% | -74% | +17% | -79.02 | 6.01 | 5.04 | 33.27 | — | 6.18 | 54.63% | 11.40% | 8.71% | -8.59% | 27.89% | -6.43% | 0.02 | — | 3.79 | 3.09 | -1.73 | -22500.00% | 6009.00% | 0.00% | 0.74% | 0.18 | 13.82% | 0.00% | 0.00% | 0.23% | 38.96 | 118.40 | 4.44 | 11.43 |
| MGTX | MeiraGTx Holdings plc | $7.56 | 608.51M | +360% | -66% | — | — | -3.01 | 6.57 | 13.39 | -3.51 | -7.13 | 6.65 | 28.51% | -493.44% | -444.10% | -143.48% | -223.66% | -49.55% | 1.25 | -12.37 | 2.03 | 1.88 | 0.15 | 4228.00% | 13742.00% | -1282.00% | -24.57% | -1.72 | -149.07% | 0.00% | 0.00% | 0.00% | -2.60 | -3.90 | 12.82 | -3.93 |
| NUVL | Nuvalent, Inc. | $101.95 | 7.41B | — | — | — | — | -17.31 | 5.90 | — | -571.33 | -35.43 | 5.90 | 0.00% | — | — | -36.70% | 481.41% | -33.30% | 0.00 | — | 15.27 | 15.05 | 24.96 | 4885.00% | — | 4871.00% | -3.74% | -3.02 | 319.78% | 0.00% | 0.00% | 1.58% | -14.46 | -21.77 | — | 26.05 |
| PLRX | Pliant Therapeutics, Inc. | $1.30 | 79.88M | +1,747% | — | — | — | -0.47 | 0.32 | — | 0.96 | -1.78 | 0.32 | 0.00% | — | — | -54.09% | 61060.16% | -46.27% | 0.20 | -75.52 | 10.91 | 10.78 | 0.05 | 2618.00% | -10000.00% | 3587.00% | -162.48% | -4.68 | 42607.22% | 0.00% | 0.00% | 0.00% | 0.86 | 1.24 | — | -2.77 |
| PTGX | Protagonist Therapeutics,… | $92.08 | 5.76B | -20% | -55% | — | +72% | — | 9.75 | 130.20 | -42.43 | — | 9.75 | 97.34% | -343.63% | -282.83% | 0.00% | -97.33% | 0.00% | 0.02 | — | 12.71 | 12.49 | 0.92 | -14846.00% | -8941.00% | -6932.00% | 0.94% | 1.27 | 34.52% | 0.00% | — | 0.53% | -34.37 | 96.90 | 118.09 | 66.47 |
| QURE | uniQure N.V. | $15.63 | 962.87M | +52% | -69% | — | — | -2.48 | -88.12 | 21.94 | -1.83 | — | -5.94 | 32.42% | -679.58% | -883.35% | -238.46% | 63.55% | -34.51% | -9.78 | -2.89 | 9.74 | 9.32 | 0.58 | -2396.00% | 7117.00% | 2157.00% | -31.28% | -4.56 | 64.17% | 0.00% | 0.00% | 0.00% | -1.59 | -1.58 | 10.82 | -2.50 |
| RCKT | Rocket Pharmaceuticals, I… | $5.01 | 542.19M | — | — | — | — | -2.48 | 1.99 | — | -2.38 | — | 2.59 | 0.00% | — | — | -60.27% | -135.95% | -52.00% | 0.09 | -122.55 | 6.38 | 2.57 | 0.25 | -2637.00% | — | -1166.00% | -34.48% | -6.29 | -111.72% | 0.00% | 0.00% | 0.00% | -2.16 | -2.62 | — | -1.60 |
| RLAY | Relay Therapeutics, Inc. | $10.26 | 1.78B | +180% | -62% | — | — | -6.08 | 2.96 | 109.40 | -5.44 | — | 2.96 | 76.83% | -1971.59% | -1800.58% | -41.12% | -108.03% | -37.05% | 0.06 | — | 22.61 | 3.28 | 0.17 | -3178.00% | 5344.00% | -608.00% | -14.04% | -9.21 | -84.17% | 0.00% | 0.00% | 0.06% | -5.38 | -6.90 | 106.04 | 13.52 |
| RNA | Avidity Biosciences, Inc. | $14.75 | 2.28B | +47% | -35% | — | — | -3.00 | 1.22 | 109.48 | -0.66 | -4.17 | 1.22 | 77.87% | -3977.30% | -3650.39% | -43.98% | -9010.06% | -38.88% | 0.06 | — | 9.20 | 8.75 | 0.42 | 7197.00% | 7211.00% | 11555.00% | -32.33% | -3.33 | -8017.39% | 0.00% | 0.00% | 3.65% | -0.60 | -0.68 | 24.04 | 3.18 |
| RVMD | Revolution Medicines, Inc… | $102.02 | 19.72B | — | — | — | — | -17.08 | 11.84 | — | -16.01 | -25.80 | 12.38 | 0.00% | — | — | -58.07% | 1908.09% | -46.06% | 0.10 | -48.80 | 7.14 | 6.97 | 0.21 | 6620.00% | — | 6094.00% | -4.73% | -3.09 | 1474.57% | 0.00% | 0.00% | 0.00% | -14.76 | -19.10 | — | 13.58 |
| SLDB | Solid Biosciences Inc. | $6.21 | 483.82M | — | — | — | — | -1.77 | 1.61 | — | -0.79 | — | 1.61 | 0.00% | — | — | -94.57% | -623.56% | -70.53% | 0.18 | -381.55 | 5.20 | 4.92 | 0.46 | -3665.00% | — | 519.00% | -45.50% | -3.31 | -483.87% | 0.00% | 0.00% | 6.07% | -0.74 | -0.96 | — | -4.69 |
| SNDX | Syndax Pharmaceuticals, I… | $21.71 | 1.89B | +262% | +64,186% | — | — | -6.72 | 29.67 | 11.13 | -6.06 | — | 29.67 | 95.96% | -158.45% | -165.60% | -161.82% | 196.12% | -45.50% | 0.00 | -8.08 | 4.40 | 3.60 | 0.54 | -1153.00% | 62784.00% | 1756.00% | -16.85% | -2.69 | 232.09% | 0.00% | 0.00% | 17.03% | -5.58 | -4.71 | 8.84 | -1.10 |
| STOK | Stoke Therapeutics, Inc. | $36.41 | 2.08B | +35% | +5,275% | — | — | -4.86 | 1.89 | 11.83 | -2.20 | — | 1.89 | 100.00% | -277.31% | -243.42% | -45.80% | 800.63% | -35.60% | 0.01 | — | 5.81 | 5.43 | 1.27 | -3067.00% | 31634.00% | 529.00% | -20.12% | -2.17 | 687.55% | 0.00% | 0.00% | 0.00% | -2.15 | -2.50 | 5.96 | 3.33 |
| VRDN | Viridian Therapeutics, In… | $29.38 | 2.39B | +11,973% | +7,221% | — | — | -7.49 | 3.55 | 36.21 | -5.16 | — | 3.55 | 98.36% | -512.91% | -483.57% | -49.16% | 573.89% | -41.73% | 0.07 | -73.44 | 12.65 | 12.37 | 0.48 | -1658.00% | 2335993.00% | 1892.00% | -10.79% | -3.91 | 437.27% | 0.00% | 0.00% | 3.24% | -4.79 | -6.29 | 24.58 | 6.44 |
| VTYX | Ventyx Biosciences, Inc. | $13.97 | 1B | — | — | — | — | -0.76 | 0.40 | — | 0.71 | — | 0.40 | 0.00% | — | — | -54.27% | -573.99% | -48.76% | 0.04 | — | 17.97 | 17.09 | 0.11 | -4030.00% | — | -2151.00% | -128.50% | -10.24 | -506.96% | 0.00% | 0.00% | 0.00% | 0.70 | 0.80 | — | -0.92 |
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
- CEO
- David Meeker
- Employees
- 283
- Beta
- 2.01
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($292.32 ÷ $81.81) − 1 = +257.32% (DCF, example).